A-TANGO is an international Project, lasting 5 years, financed with 6 million euros from the European funds Horizon 2020,and in which more tan 10 international european entities participate, including Alpha Bioresearch. Designed to determinate efficacy of a novel therapy against chronic liver failure, A-TANGO is a Phase II clinical trial, developed in 10 european countries that (which) could mean a 20% improvement in the survival rate in patients with chronic liver failure. This project will offer new hope to patients with cirrhosis and provide new insights into the underlying pathophysiological mechanisms that cause decompensated cirrosis, alcoholic decompensated liver disease and chronic liver failure. Furthermore, biomarkers will be identified that will allow patients to be stratified improving the outcome of their treatment.
The impact of A-TANGO could result in the removal of approximately 12.000 patients from the transplant list, and savings of up to 720 million euros.
Alpha Bioresearch has been chosen to lead this project as a Clinical Research Global Hub CRO with extensive experience in the development of international projects funded by the EU and with a portfolio of comprehensive services suitable for studies of this magnitude.
- The entities that are part of the A-TANGO consortium:
- Alpha Bioresearch S.L. (ABR), Spain.
- Paris Assistance Public Hospital (APHP), France
- Berlin Charité University Hospital (Charité), Germany.
- Concentris research management gmbh (concetris), Germany.
- Crowdhelix Ltd (CHX), Ireland.
- European Association for the Study of the Liver, Switzeland.
- European Fundation for the Study of Chronic Liver Failure (EFCLIF), Spain.
- European Liver Patients’s Association
- Hepux Ldt. (HPX), United Kindom.
- International Market Acess Consulting GmbH (IMAC), Switzerland.
- Leiden University Medical Center (LUMC), Netherlands.
- Leipzig University (ULEI), Germany.
- University College London (UCL), United Kindom
- Yaqrit Ltd. (YAQ), United Kindom.
The European Fundation for the Study of Chronic Liver Failure (EFCLIF, in red), coordinates A-TANGO, a five-years cooperative research Project with 14 European partner instutions. This Project has received from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 945096. This press release reflects the views of the authors only, and the European Comission is not responsible for any use that may be made of the information it contains.